{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:26:15Z","timestamp":1788395175385,"version":"build-2803163510"},"reference-count":50,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"High-end Talent Introduction \u201cDouble Hundred Plan\u201d Special Foundation of Yantai City","award":["612211012002"],"award-info":[{"award-number":["612211012002"]}]},{"name":"High-end Talent Introduction \u201cDouble Hundred Plan\u201d Special Foundation of Yantai City","award":["ZR2023MC059"],"award-info":[{"award-number":["ZR2023MC059"]}]},{"name":"Natural Science Foundation of Shandong, China","award":["612211012002"],"award-info":[{"award-number":["612211012002"]}]},{"name":"Natural Science Foundation of Shandong, China","award":["ZR2023MC059"],"award-info":[{"award-number":["ZR2023MC059"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>The BCR-ABL1 fusion protein is a critical therapeutic target in Chronic Myeloid Leukemia (CML). Current monotherapy approaches involve types of inhibitors that can be categorized into ATP competitive inhibitors and allosteric inhibitors. However, resistance mutations in the tyrosine kinase domain of BCR-ABL1 have limited the effectiveness of these drugs. Research indicates that dual inhibition of BCR-ABL1 by combining these two types of inhibitors effectively addresses the issue of drug resistance as there are no overlapping resistance mechanisms. However, the underlying reasons for the observed synergistic effects have not yet been thoroughly elucidated. In this study, we employed molecular dynamics simulation to observe the synergistic interactions of BCR-ABL1 by the allosteric inhibitor asciminib and ATP competitive inhibitors nilotinib and ponatinib. Our study reveals that when asciminib binds to BCR-ABL1, nilotinib and ponatinib exhibit more substantial binding stability compared to monotherapy. At the atomic level, we have elucidated the reasons for the enhanced binding affinity of nilotinib and ponatinib when using a co-inhibition therapy. Our study reveals the allosteric communication pathway between asciminib and ponatinib, providing more detailed insights into the effectiveness of combination therapy. These findings provide valuable insights into combination therapies, aiding in the rational use of medications and guiding the design of novel inhibitors.<\/jats:p>","DOI":"10.3390\/biom15091214","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T11:50:31Z","timestamp":1755863431000},"page":"1214","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Exploring the Allosteric Pathways of Asciminib in the Dual Inhibition of BCR-ABL1"],"prefix":"10.3390","volume":"15","author":[{"given":"Jie","family":"Ming","sequence":"first","affiliation":[{"name":"School of Life Science, Ludong University, Yantai 264025, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Gao","sequence":"additional","affiliation":[{"name":"School of Life Science, Ludong University, Yantai 264025, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7797-1187","authenticated-orcid":false,"given":"Jiuyu","family":"Zhan","sequence":"additional","affiliation":[{"name":"School of Life Science, Ludong University, Yantai 264025, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ajh.25792","article-title":"Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring","volume":"95","author":"Jabbour","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","article-title":"Response and Resistance to BCR-ABL1-Targeted Therapies","volume":"37","author":"Braun","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"155161","DOI":"10.1016\/j.prp.2024.155161","article-title":"The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia","volume":"254","author":"Nsairat","year":"2024","journal-title":"Pathol.-Res. Pract."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41375-023-02122-5","article-title":"In vitro evidence of synergistic efficacy with asciminib combined with reduced dose of ATP-binding pocket tyrosine kinase inhibitors according to the ABL1 kinase domain mutation profile","volume":"38","author":"Han","year":"2023","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1172\/JCI31691","article-title":"Treatment for chronic myelogenous leukemia: The long road to imatinib","volume":"117","author":"Hunter","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-38672-x","article-title":"Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients","volume":"9","author":"Chandrasekhar","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1038\/leusup.2012.22","article-title":"Second-generation TKIs: Which and when?","volume":"1","author":"Saglio","year":"2012","journal-title":"Leuk. Suppl."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40259-013-0056-z","article-title":"Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML)","volume":"28","author":"Abruzzese","year":"2013","journal-title":"BioDrugs"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminoncol.2011.01.016","article-title":"Nilotinib: A Novel, Selective Tyrosine Kinase Inhibitor","volume":"38","author":"Blay","year":"2011","journal-title":"Semin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Nascimento, M., Moura, S., Parra, L., Vasconcellos, V., Costa, G., Leite, D., Dias, M., Fernandes, T.V.A., Hoelz, L., and Pimentel, L. (2024). Ponatinib: A Review of the History of Medicinal Chemistry behind Its Development. Pharmaceuticals, 17.","DOI":"10.3390\/ph17101361"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/sj.bjc.6603170","article-title":"AMN107 (nilotinib): A novel and selective inhibitor of BCR-ABL","volume":"94","author":"Weisberg","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.drudis.2013.06.001","article-title":"The background, discovery and clinical development of BCR-ABL inhibitors","volume":"18","author":"Lambert","year":"2013","journal-title":"Drug. Discov. Today"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1021\/acschembio.5b01018","article-title":"Conformation-Selective Analogues of Dasatinib Reveal Insight into Kinase Inhibitor Binding and Selectivity","volume":"11","author":"Kwarcinski","year":"2016","journal-title":"ACS. Chem. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"106458","DOI":"10.1016\/j.leukres.2020.106458","article-title":"The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase","volume":"98","author":"Manley","year":"2020","journal-title":"Leuk. Res."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Tamai, M., Inukai, T., Kojika, S., Abe, M., Kagami, K., Harama, D., Shinohara, T., Watanabe, A., Oshiro, H., and Akahane, K. (2018). T315I mutation of BCR-ABL1 into human Philadelphia chromosome-positive leukemia cell lines by homologous recombination using the CRISPR\/Cas9 system. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-27767-6"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1038\/leu.2009.69","article-title":"The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR\/ABL","volume":"23","author":"Mian","year":"2009","journal-title":"Leukemia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia","volume":"26","author":"Zabriskie","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.bbagen.2019.01.011","article-title":"The catalytic activity of Abl1 single and compound mutations: Implications for the mechanism of drug resistance mutations in chronic myeloid leukaemia","volume":"1863","author":"Georgoulia","year":"2019","journal-title":"Biochim. Biophys. Acta (BBA)-Gen. Subj."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1182\/blood-2019-129579","article-title":"Dynamic Evolution of Ponatinib Resistant BCR-ABL1 T315 and Compound Mutations","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.exphem.2018.08.006","article-title":"Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: The PEARL observational study","volume":"67","author":"Heiblig","year":"2018","journal-title":"Exp. Hematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"7581","DOI":"10.1021\/acs.jmedchem.2c00373","article-title":"The Dawn of Allosteric BCR-ABL1 Drugs: From a Phenotypic Screening Hit to an Approved Drug","volume":"65","author":"Teng","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1358\/dot.2022.58.10.3441853","article-title":"Asciminib in chronic myeloid leukemia","volume":"58","author":"Assanto","year":"2022","journal-title":"Drugs Today"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2020-140968","article-title":"Structural and Biochemical Studies Confirming the Mechanism of Action of Asciminib, an Agent Specifically Targeting the ABL Myristoyl Pocket (STAMP)","volume":"136","author":"Schuld","year":"2020","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","article-title":"Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1","volume":"61","author":"Schoepfer","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-022-30258-y","article-title":"Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors","volume":"13","author":"Beyett","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_28","first-page":"1","article-title":"The effects of combination treatments on drug resistance in chronic myeloid leukaemia: An evaluation of the tyrosine kinase inhibitors axitinib and asciminib","volume":"20","author":"Friedman","year":"2020","journal-title":"BMC. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e202117276","DOI":"10.1002\/anie.202117276","article-title":"Correspondence on \u201cSynergy and Antagonism between Allosteric and Active-Site Inhibitors of Abl Tyrosine Kinase\u201d","volume":"61","author":"Jahnke","year":"2022","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e2304611120","DOI":"10.1073\/pnas.2304611120","article-title":"A biophysical framework for double-drugging kinases","volume":"120","author":"Kim","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e1214","DOI":"10.1002\/prp2.1214","article-title":"Asciminib, a novel allosteric inhibitor of BCR-ABL1, shows synergistic effects when used in combination with imatinib with or without drug resistance","volume":"12","author":"Okamoto","year":"2024","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR\u2013ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s10930-019-09820-z","article-title":"A Synergistic Combination Against Chronic Myeloid Leukemia: An Intra-molecular Mechanism of Communication in BCR\u2013ABL1 Resistance","volume":"38","author":"Soliman","year":"2019","journal-title":"Protein J."},{"key":"ref_34","first-page":"4470","article-title":"Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 T315I-compound mutations","volume":"11","author":"Gleixner","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"El Rashedy, A.A., Olotu, F.A., and Soliman, M.E.S. (2018). Dual Drug Targeting of Mutant Bcr-Abl Induces Inactive Conformation: New Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming Monotherapy Resistance. Chem. Biodivers., 15.","DOI":"10.1002\/cbdv.201700533"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"W368","DOI":"10.1093\/nar\/gki464","article-title":"H++: A server for estimating pKas and adding missing hydrogens to macromolecules","volume":"33","author":"Gordon","year":"2005","journal-title":"Nucleic Acids Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/jcc.20290","article-title":"The Amber biomolecular simulation programs","volume":"26","author":"Case","year":"2005","journal-title":"J. Comput. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/jcc.20035","article-title":"Development and testing of a general amber force field","volume":"25","author":"Wang","year":"2004","journal-title":"J. Comput. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","article-title":"ff14SB: Improving the accuracy of protein side chain and backbone parameters from ff99SB","volume":"11","author":"Maier","year":"2015","journal-title":"J. Chem. Theory Comput."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/ct1003687","article-title":"Explicit Water Models Affect the Specific Solvation and Dynamics of Unfolded Peptides While the Conformational Behavior and Flexibility of Folded Peptides Remain Intact","volume":"6","author":"Otyepka","year":"2010","journal-title":"J. Chem. Theory Comput."},{"key":"ref_41","unstructured":"(2024, July 13). Amber 2024. Available online: https:\/\/ambermd.org\/CiteAmber.php."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1021\/ar000033j","article-title":"Calculating Structures and Free Energies of Complex Molecules: Combining Molecular Mechanics and Continuum Models","volume":"33","author":"Kollman","year":"2000","journal-title":"Accounts Chem. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1039\/C7CP08241J","article-title":"Importance of protein flexibility in molecular recognition: A case study on Type-I1\/2 inhibitors of ALK","volume":"20","author":"Kong","year":"2018","journal-title":"Phys. Chem. Chem. Phys."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"22035","DOI":"10.1039\/C4CP03179B","article-title":"Assessing the performance of MM\/PBSA and MM\/GBSA methods. Improved docking performance using high solute dielectric constant MM\/GBSA and MM\/PBSA rescoring","volume":"16","author":"Sun","year":"2014","journal-title":"Phys. Chem. Chem. Phys."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Federico, L.B., Silva, G.M., Gomes, S.Q., Francischini, I.A.G., Barcelos, M.P., dos Santos, C.B.R., Costa, L.T., Rosa, J.M.C., and Silva, C.H.T.d.P.d. (2021). Potential colchicine binding site inhibitors unraveled by virtual screening, molecular dynamics and MM\/PBSA. Comput. Biol. Med., 137.","DOI":"10.1016\/j.compbiomed.2021.104817"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/bioinformatics\/btu718","article-title":"WebPSN: A web server for high-throughput investigation of structural communication in biomacromolecules","volume":"31","author":"Seeber","year":"2014","journal-title":"Bioinformatics"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.csbj.2021.12.044","article-title":"PSNtools for standalone and web-based structure network analyses of conformational ensembles","volume":"20","author":"Felline","year":"2022","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e2730","DOI":"10.1002\/jmr.2730","article-title":"Exploring the inhibition mechanism on HIF-2 by inhibitor PT2399 and 0X3 using molecular dynamics simulations","volume":"31","author":"Sun","year":"2018","journal-title":"J. Mol. Recognit."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Kasahara, K., Fukuda, I., Nakamura, H., and Agarwal, P.K. (2014). A Novel Approach of Dynamic Cross Correlation Analysis on Molecular Dynamics Simulations and Its Application to Ets1 Dimer\u2013DNA Complex. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0112419"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41375-024-02248-0","article-title":"Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations","volume":"38","author":"Curik","year":"2024","journal-title":"Leukemia"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/9\/1214\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:33:45Z","timestamp":1760034825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/9\/1214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":50,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["biom15091214"],"URL":"https:\/\/doi.org\/10.3390\/biom15091214","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]}}}